Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $35.8, Implies 18% Upside

Analysts raised Alamar Biosciences' 12-month price target from $35.4 to $35.8, with a range of $31 to $45. This implies an 18% upside from the Nov. 3 closing price. The consensus rating remains 'Buy' with 4 Buys, 1 Hold, and 0 Sells.

Original reporting
Published Nov 4, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 7:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $35.8, Implies 18% Upside — source image
Decision brief

The 30-second read

$ALMRBullishLow
01

Why it matters

Analyst consensus remains a Buy, reinforcing positive sentiment despite modest target change.

02

Market read

The price‑target upgrade provides a small but actionable signal for traders monitoring micro‑cap biotech stocks.

03

What to watch

Potential dilution from upcoming financing rounds not reflected in the target.

Relevance 5/10Novelty 4/10Timing: post‑market today

Background

Alamar Biosciences is a clinical‑stage biotech focused on oncology therapies.

Company-level read

Ticker impact

$ALMRBullishHigh confidence
Context

Analysts raised Alamar Biosciences' average price target to $35.8, implying ~18% upside from the recent close.

Expected impact

likely modest upside as investors price in the raised target

Evidence & confidence

Price‑target upgrades are a direct catalyst; the 18% implied upside may attract short‑term interest.

Market effects

Small‑cap biotech sector may see slight uplift from analyst optimism.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact; confined to niche biotech investors.

Counterpoint

The target raise may be premature if upcoming trial data disappoints.

Key entities

  • Alamar Biosciences, Inc.

    Biotech firm whose price target was raised.

Related articles

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue growth of 68% YoY, with consumables up 79%. Gross margin improved to 61.5%. The company raised full-year guidance and announced partnerships with U.K. Biobank and GSK, totaling over 140,000 samples. ALMR added 35 publications, bringing the total to over 200, and strengthened its leadership team.

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with gross margin at 61.5%. Net loss was $13.3M. Full-year revenue guidance raised to $121M-$123M. Company finalized large-scale studies with UK Biobank and GSK, focusing on neurodegenerative and inflammatory diseases. Cash position at $231.5M supports expansion plans. President Todd White to retire by year-end.

$ALMRMed

Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68%

Alamar Biosciences Inc (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with consumables revenue representing 53% of total revenue. Gross margin reached 61.5%. Full-year guidance was raised to $121-123M. Net loss widened to $13.3M. The company secured partnerships with UK Biobank and GSK. Q4 revenue guidance implies flat sequential growth, raising concerns about near-term momentum.

$ALMRMed

Alamar Biosciences Q3 Earnings Call Highlights

Alamar Biosciences (ALMR) reported Q3 earnings, with revenue up 64% YoY. Key projects include UK Biobank work and a GSK partnership. Biopharma customers now represent 49% of revenue. Gross profit rose to $20.6M, but operating loss widened to $15.1M. The company raised its 2026 revenue guidance to $121M-$123M. ALMR plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027.

Med

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

$ALMRMed

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o